Omeros Corp reports additional positive data from its oms824 phase 2a schizophrenia clinical trial


Thursday, 6 Mar 2014 07:00am EST 

Omeros Corp:Says additional positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor.Patients with schizophrenia were administered a higher dose than had been evaluated in any OMS824 trial, which resulted in about 50 pct higher plasma concentrations than did the previously reported highest dose and had a similar side-effect profile to those of the lower doses.OMS824 inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease.The results reported today were in psychiatrically stable patients who continued their usual antipsychotic regimen and received OMS824 or placebo for 14 days.The positive results across all doses tested in this Phase 2a trial indicate that OMS824 can be administered in combination with standard antipsychotic medications.Says that, at tolerated doses, yields plasma concentrations that are predicted to achieve a high degree of PDE10 target interaction in the striatum. 

Company Quote

20.12
-0.52 -2.52%
21 Nov 2014